Lyra Therapeutics (LYRA)

• Market cap: $12.3M
• 1 day: -7.36%
• 5 days: -5.08%
• 1 month: -12.96%
• 3 months: 57.63%
• 6 months: -32.22%
• Year to date: -35.93%
• 1 year: -59.58%
• 5 years: -98.99%
• 10 years: -99.25%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Employees: 30

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

37% more capital invested

Capital invested by funds: $3.23M [Q1] → $4.42M (+$1.19M) [Q2]

1.58% less ownership

Funds ownership: 38.85% [Q1] → 37.28% (-1.58%) [Q2]

47% less funds holding

Funds holding: 57 [Q1] → 30 (-27) [Q2]

76% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 34

90% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 20

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $16 131% upside
• Avg. target: $16 131% upside
• High target: $16 131% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield

131% upside $16

Neutral Reiterated

14 Aug 2025